Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL821037 | 0.76 | MEN1 (1.00) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| Eprenetapopt SCHEMBL21636035 | 0.70 | MEN1 (0.72) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2931285 | 0.69 | MEN1 (0.50) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2859479 | 0.69 | MEN1 (0.50) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2965105 | 0.68 | MEN1 (0.54) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL4367365 | 0.68 | MEN1 (0.35) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL21063706 | 0.67 | MEN1 (0.48) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL2923818 | 0.66 | MAPT (0.51) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL13238712 | 0.66 | MEN1 (0.56) | MEN1MAPTCYP2C9CYP2C19KMT2A | |
| SCHEMBL13238651 | 0.66 | MEN1 (0.56) | MEN1MAPTCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-7687630-B2 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081911-A1 | Method for producing optically active quinuclidinols having one or more substituted groups at the 2-position | NQO1, SQLE, NQO2 | MEN1 497/4885MAPT 4361/4885CYP2C9 304/4885 |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | MEN1 3708/4885MAPT 2486/4885CYP2C9 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.